Pfizer has acquired the worldwide rights to sell insulin and insulin analogs being developed by Indian biotech company Biocon, in an attempt to work its way into the generic biotech drug market, says the New York Times' Andrew Pollack in the Prescriptions blog. Pfizer will pay Biocon $200 million initially, and then another $150 million, while Biocon manufactures the insulin. Other pharma companies are also getting into the biologic market, Pollack says. Merck, for example, has a business unit dedicated to biosimilars. And the health care reform law requires FDA to develop a system to approve such biotech generics, Pollack adds. The agency is holding a meeting in November to seek input on how to set up such a system.
Pfizer Hearts Biologic Drugs
Oct 19, 2010